Anumigilimab（Cat No.:I042174）is an investigational monoclonal antibody that targets the immune checkpoint receptor TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), which is expressed on T-cells and plays a role in immune suppression. By inhibiting TIM-3, anumigilimab aims to enhance T-cell activation and restore the immune system’s ability to recognize and attack cancer cells. It is being studied in clinical trials for its potential in treating various cancers, including solid tumors and hematologic malignancies. The goal is to improve immune responses and patient outcomes, particularly in combination with other immunotherapies.
